Key result
SARS-CoV-2 infection is associated with severe cardiovascular complications including MI, myocarditis, arrhythmias, and VTE.
COVID-19 is associated with significant cardiovascular complications and worse outcomes in patients with pre-existing cardiometabolic conditions.
Requires vigilance for cardiac events in COVID-19; leaves open optimal prevention strategies pending prospective trials.
SARS-CoV-2 has driven the COVID-19 epidemic around the world, making it one of the most significant medical challenges of the last century. This infectious agent infects host cells by binding to ACE2 receptors (an enzyme present in several tissues, such as the heart, lung and kidneys) and can lead to pneumonia, acute myocardial damage and chronic damage to the cardiovascular system. Pre-existing conditions such as diabetes, hypertension and obesity are related to greater severity and a significant increase in the fatality rate of COVID-19. The exacerbated production of inflammatory cytokines such as IL-6 and TNF-α leads to systemic inflammation, which can directly affect the cardiovascular system. Acute myocardial infarction (increased risk), myocarditis, arrhythmias, venous thromboembolism and takotsubo cardiomyopathy are some of the most prevalent complications of the cardiovascular system described in patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Dorigo et al. (2023) conducted a review in COVID-19. SARS-CoV-2 infection was evaluated. SARS-CoV-2 infection can lead to severe cardiovascular complications, including acute myocardial infarction, myocarditis, arrhythmias, venous thromboembolism, and takotsubo cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: